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ABSTRACT: We compared the reproducibility of multiple
reaction monitoring (MRM) mass spectrometry-based peptide
quantitation in tryptic digests from formalin-ﬁxed, paraﬃn-
embedded (FFPE) and frozen clear cell renal cell carcinoma
tissues. The analyses targeted a candidate set of 114 peptides
previously identiﬁed in shotgun proteomic analyses, of which
104 were detectable in FFPE and frozen tissue. Although
signal intensities for MRM of peptides from FFPE tissue were
on average 66% of those in frozen tissue, median coeﬃcients of
variation (CV) for measurements in FFPE and frozen tissues
were nearly identical (18−20%). Measurements of lysine C-terminal peptides and arginine C-terminal peptides from FFPE tissue
were similarly reproducible (19.5% and 18.3% median CV, respectively). We further evaluated the precision of MRM-based
quantitation by analysis of peptides from the Her2 receptor in FFPE and frozen tissues from a Her2 overexpressing mouse
xenograft model of breast cancer and in human FFPE breast cancer specimens. We obtained equivalent MRM measurements of
HER2 receptor levels in FFPE and frozen mouse xenografts derived from HER2-overexpressing BT474 cells and HER2-negative
Sum159 cells. MRM analyses of 5 HER2-positive and 5 HER-negative human FFPE breast tumors conﬁrmed the results of
immunohistochemical analyses, thus demonstrating the feasibility of HER2 protein quantiﬁcation in FFPE tissue specimens. The
data demonstrate that MRM analyses can be performed with equal precision on FFPE and frozen tissues and that lysine-
containing peptides can be selected for quantitative comparisons, despite the greater impact of formalin ﬁxation on lysine
residues. The data further illustrate the feasibility of applying MRM to quantify clinically important tissue biomarkers in FFPE
specimens.
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■ INTRODUCTION
A growing body of literature has provided robust evidence that
formalin ﬁxed, paraﬃn-embedded (FFPE) tissue can be
successfully analyzed using mass spectrometry-based proteomic
methods, enabling the use of these archival specimens for
biomarker discovery through retrospective analysis.
1−5
Although qualitative protein identiﬁcations can be obtained
from ﬁxed tissue, ﬁxation leads to covalent chemical
modiﬁcation and cross-linking of proteins, DNA and RNA,
which may be expected to aﬀect the quantitative reliability of
FFPE tissue analyses by targeted proteomic methods, such as
multiple reaction monitoring (MRM). Recently, research
eﬀorts have begun to demonstrate the technical feasibility of
targeted quantitative proteomic analysis in FFPE tissue.
6−8
Huang et al. described the shotgun proteomic analysis of laser
capture microdissected FFPE primary and metastatic melano-
mas and identiﬁed 120 proteins as potential markers of
metastasis.
7 Label-free quantitation was performed with
extracted MS1 signal from an ion trap MS instrument. Güzel
et al. analyzed calcyclin peptides by selected reaction
monitoring (one transition per peptide) on a triple quadrupole
instrument with sequence analogue peptides as reference
standards.
6 Similarly, Nishimura et al. quantiﬁed two potential
prognostic markers for lung adenocarcinoma in FFPE tissue
using an endogenous β-actin peptide as an internal standard.
8
Although these reports have demonstrated the application of
targeted protein analyses of FFPE tissue, the critical issue of
how formalin ﬁxation aﬀects the precision of quantitative
analyses in FFPE tissues remains unexplored. Because form-
aldehyde chemistry signiﬁcantly aﬀects lysine C-terminal
peptides, it is not clear whether quantitative strategies must
be adjusted to avoid these.
To assess the impact of ﬁxation on the reproducibility of
peptide quantitation, we compared the MRM signals for tryptic
peptides derived from paired ﬁxed and frozen clear cell renal
cell carcinoma (RCC) tissue from the same tumor. Our
analyses describe the precision of measurements of a large set
of tryptic peptides across a broad concentration range in both
FFPE and frozen specimens. We further evaluated the precision
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from the HER2 (ERBB2) receptor in FFPE and frozen tissues
from a mouse xenograft model of HER2 overexpressing breast
cancer. Finally, we used MRM analyses to quantify HER2
protein in FFPE specimens of immunohistochemically




Sub-X xylene substitute was obtained from Surgipath
(Richmond, IL). Iodoacetamide (IAM) was from Sigma (St.
Louis, MO), tris-carboxyethylphosphine (TCEP) was from
Pierce (Rockford, IL), sequencing grade trypsin was from
Promega (Madison, WI), triﬂuoroethanol and dithiothreitol
(DTT) were from Acros (Geel, Belgium). Triﬂuoroacetic acid,
ammonium bicarbonate, and urea were purchased from
ThermoFisher Scientiﬁc (Waltham, MA).
Tissue Digest
The deidentiﬁed human tissue samples and experimental
protocol were subject to Institutional Review Board exempt
approval (Institutional Review Board Protocols 080856 and
110453). Fixed and frozen RCC tissues were obtained from the
Cooperative Human Tissue Network-Western Division (Van-
derbilt University, Nashville, TN). FFPE human breast cancer
tissue blocks were obtained through the Vanderbilt-Ingram
Cancer Center Breast Cancer SPORE Tissue Core. Fixed and
frozen mouse xenografts of BT474 (HER2+) and Sum159
(HER2 negative) cell lines were kindly provided by the
laboratory of Carlos L. Arteaga.
Slices of tissue (30 μm) were placed in separate Eppendorf
tubes. Paraﬃn was removed with three washes of 1 mL of Sub-
X and tissue was rehydrated with 2 × 1 mL washes each of
100%, 85%, and 70% ethanol. Deparaﬃnized, rehydrated tissue
slices were resuspended in 100 μL of ammonium bicarbonate
(100 mM, pH 8.0) and were heated at 80 °C for 2 h. Tryptic
digestion was done by an adaptation of the method of Wang et
al.
9 Triﬂuoroethanol (TFE) (100 μL) was added and the
samples were sonicated for 20 s followed by 30 s incubation on
ice. The sonication was repeated twice. The resulting
homogenate was heated for 1 h at 60 °C followed by a second
series of sonication steps, as described above. The homogenate
was reduced with tris-(carboxyethyl)phosphine (10 mM) and
dithiothreitol (25 mM) at 60 °C for 30 min, followed by
alkylation with iodoacetamide (50 mM) in the dark at ambient
temperature for 20 min. The reduced and alkylated protein
mixture was diluted to 1 mL with ammonium bicarbonate (50
mM, pH 8.0) followed by addition of trypsin at 1:50 (w/w).
The digest was incubated overnight at 37 °C, followed by
freezing at −80 °C and lyophilization. Samples were
resuspended in 1 mL of water, desalted over 1 cm3 (100 mg)
Sep-Pak vac C-18 cartridges (Waters Corp., Milford, MA), and
evaporated to dryness in vacuo with a Speed-Vac sample
concentrator (ThermoFisher, Waltham, MA).
Isoelectric Focusing of Peptides
Isoelectric focusing (IEF) of tryptic peptides was performed by
a modiﬁcation of the method described previously.
5 Four
replicate IEF strips were run for digests of FFPE and frozen
tissue. RCC tryptic peptides (200 μg) were resuspended in 500
μL of 6 M urea and loaded in an IPGphor rehydration tray.
Immobiline immobilized pH gradient strips (24 cm, pH 3.5−
4.5) were placed over the samples and allowed to rehydrate
overnight at ambient temperature. The loaded strips were
focused at 21 °C on an Ettan IPGPhor-3 IEF system (GE
Healthcare, Piscataway, NJ) using the following program: step
at 300 V for 900 Vh; gradient to 1000 V for 3900 Vh; gradient
to 8000 V for 13500 Vh; step to 8000 V for 93700 Vh. The
strips were then cut into 20 (1.2 cm) pieces and placed in
separate wells of a 96-well ELISA plate. Peptides were eluted
from the strips as follows: 200 μL of 0.1% formic acid (FA) for
15 min; 200 μL of 50% acetonitrile (ACN)/0.1% FA for 15
min; 200 μL of 100% ACN/0.1% FA for 15 min. Solutions of
extracted peptides were evaporated in vacuo, resuspended in 1
mL 0.1% triﬂuoroacetic acid, and desalted over a 96-well C18
Oasis HLB plate 30 μm (10 mg) (Waters Corp., Milford, MA).
Peptide solutions were evaporated in vacuo, resuspended in
100 μL of 0.1% FA, and placed in sample vials for liquid
chromatography−tandem mass spectrometry (LC−MS/MS)
analysis.
Reverse Phase LC−MS/MS Analyses
LC−MS/MS analyses were performed on an LTQ-XL mass
spectrometer (Thermo Electron, San Jose, CA) equipped with
an Eksigent 1D nanoLC and microautosampler (Dublin, CA).
Peptides were loaded on a 100 μm × 5 cm fused silica capillary
guard column (Polymicro Technologies, LLC., Phoenix, AZ)
packed with 5 μm, 300 Å Jupiter C18 (Phenomenex, Torrance,
CA) and resolved on a 100 μm × 11 cm fused silica capillary
column (Polymicro Technologies, LLC., Phoenix, AZ) packed
with 5 μm, 300 Å Jupiter C18 (Phenomenex, Torrance, CA).
Liquid chromatography was carried out at ambient temperature
at a ﬂow rate of 0.6 μL min−1 using a gradient mixture of 0.1%
(v/v) formic acid in water (solvent A) and 0.1% (v/v) formic
acid in ACN (solvent B). Peptides eluting from the capillary tip
were introduced into the LTQ source in microelectrospray
mode with a capillary voltage of approximately 2 kV. A full scan
was obtained for eluting peptides in the range of 400−2000
amu followed by six data-dependent MS/MS scans. MS/MS
spectra were recorded using dynamic exclusion of previously
analyzed precursors for 60 s with a repeat of 1 and a repeat
duration of 1. MS/MS spectra were generated by collision
induced dissociation of the peptide ions at a normalized
collision energy of 35% to generate a series of b- and y-ions as
major fragments.
MRM Analyses
MRM analyses were performed on a TSQ Vantage triple
quadurpole mass spectrometer (Thermo Electron, San Jose,
CA) equipped with an Eksigent Ultra nanoLC and micro-
autosampler (Dublin, CA). Chromatography column and
conditions were as described for LC−MS/MS analyses, except
that the ﬂow rate was reduced to 0.4 μL min−1. Analyses were
performed using the labeled referenced peptide (LRP)
method,
10 where peak areas for target peptides were normalized
against the isotope labeled β-actin peptide standard U−13C,15N-
Arg-GYSFTTTAER, which was added at a concentration of 25
nM. Four transitions were monitored for each peptide and a
maximum of 40 peptides were monitored per method.
Extracted ion chromatogram peak areas were measured as the
sum of the peak areas for the four monitored transitions.
Transitions were selected from the most intense y-ions
observed in a spectral library derived from shotgun data sets.
Spectral libraries were compiled using the Skyline software.
11
All Skyline methods are available as Supporting Information.
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The ScanSifter algorithm read tandem mass spectra stored as
centroided peak lists from Thermo RAW ﬁles and transcoded
them to mzML ﬁles.
12 If 90% of the intensity of a tandem mass
spectrum appeared at a lower m/z than that of the precursor
ion, a single precursor charge was assumed; otherwise, the
spectrum was processed under both double and triple precursor
charge assumptions. Tandem mass spectra were assigned to
peptides from the IPI Human database version 3.37 (May 5,
2008; 69 238 sequences) by the MyriMatch algorithm, version
1.6.75.
13 The sequence database was doubled to contain each
sequence in both normal and reversed orientations, enabling
false discovery rate estimation. MyriMatch was conﬁgured to
expect all cysteines to bear carboxamidomethyl modiﬁcations
and to allow for the possibility of oxidation on methionines.
Candidate peptides were required to feature trypsin cleavages
or protein termini at one end (semitryptic search); any number
of missed cleavages was permitted. A precursor error of 1.25 m/
z was allowed, but fragment ions were required to match within
0.5 m/z. The IDPicker algorithm v2.6.165.0
13 ﬁltered the
identiﬁcations for each LC−MS/MS run to include the largest
set for which a 5% identiﬁcation false discovery rate could be
maintained, as described by Qian et al.,
14 and applied
parsimonious protein assembly, reporting the smallest list of
proteins which could account for the identiﬁed peptides. These
identiﬁcations were pooled for the IEF sample set. Proteins
were required to have at least two diﬀerent peptide sequences
observed within an IEF sample set. Database protein entries
that could not be distinguished based on the observed peptides
were combined into “protein groups” representing the most
parsimonious assignment of the spectral count data. False
discovery rates (FDR) rates were computed by the formula:
15
=× + FDR (2 reverse)/(forward reverse)
The algorithm reported the number of spectra and number of
distinct sequences observed for each protein and protein group
in each sample set.
■ RESULTS
Shotgun Proteome Analysis of RCC Tissue
Shotgun proteome analysis of ﬁxed and frozen RCC tissue
indicated a qualitative concordance in protein groups identiﬁed
in both FFPE and frozen tissue (Figure 1A), as we reported
previously for comparison of frozen and FFPE tissues.
5
(Spectral count data for the identiﬁed proteins is presented
in Supporting Information Table S1; a full summary of the data
set is provided in the accompanying IDPicker report. Both are
provided as Supporting Information.) Of 2165 total protein
groups identiﬁed, 91% were found in both sample types.
However, the resulting peptide identiﬁcations obtained from
tryptic digests of ﬁxed tissue were biased against lysine C-
terminal peptides (Figure 1B). Whereas in frozen tissue the
ratio of lysine C-terminal peptides to arginine C-terminal
peptides was 1.11, the ratio in FFPE samples was reduced to
0.93. These observations are in agreement with our previous
analyses of frozen and FFPE colon adenocarcinoma tissue
5 and
are consistent with the known reactivity of aldehydes toward
primary amines, which preferentially consumes lysine residues
and thus aﬀects the yield of lysine C-terminal peptides. We thus
asked whether the modiﬁcation of lysine residues would aﬀect
the quantitation of lysine C-terminal peptides in a tryptic digest
of FFPE tissue.
Reproducibility of MRM in FFPE Tissue
To assess measurement precision in FFPE tissue, 114 peptides
were selected as MRM targets from a list of peptides identiﬁed
from shotgun proteomic analysis of IEF-fractionated tryptic
digests of FFPE and frozen RCC tissue (Supporting
Information Table S2). The peptides selected spanned the
entire range of peptide and protein abundance, as determined
by spectral count information in the shotgun data set
(Supporting Information Table S1). The 114 candidates each
were between 7 and 25 amino acids in length; contained no
methionine, cysteine, histidine, N-terminal glutamine residues
or missed tryptic cleavages; were unique to a single protein in
the search database; and were observed predominantly as
doubly charged precursors. Transitions were chosen from the 4
most intense y-ions based on reference spectra from the
shotgun data set.
The precision with which a peptide can be measured and the
intensity of the signal obtained are a function of the peptide
concentration, ionization and fragmentation characteristics,
variability in yields of sample processing steps (e.g., digestion),
and the characteristics of the instrument used to measure the
analyte. The measurement precision of the instrument can be
empirically assessed through the analysis of an internal standard
of known concentration and can provide a reference for the
measurement of eﬀects on precision caused by the ﬁxation
process. Thus, in addition to the 114 candidate peptides, an
endogenous peptide of sequence GYSFTTTAER, correspond-
ing to β-actin, was monitored, as well as an isotope labeled
version of the GYSFTTTAER peptide spiked-in at a constant
concentration of 25 nM to provide for signal normalization for
the targeted peptides and to monitor measurement precision.
16
Figure 1. Characteristics of the shotgun proteomic data set. High
qualitative concordance was observed for proteins identiﬁed in both
FFPE and frozen tissue digests. Peptides observed in FFPE tissue were
biased against lysine C-terminal peptides, indicated by a lower lysine to
arginine peptide ratio. Error bars represent standard deviation from 4
IEF replicates.
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processed in parallel and analyzed using 3 MRM acquisition
methods, which monitored 40 peptides and 160 transitions
each. The methods analyzed groups of peptide targets
corresponding to proteins of diﬀerent abundances, based on
spectral counts from the shotgun analyses. Median spectral
counts for the proteins covered in methods 1, 2, and 3 were
190, 129, and 38, respectively. The proteins and peptides
comprising the methods are listed in Supporting Information
Table S3. Lists of the transitions monitored for each peptide are
provided as Skyline (.SKY) ﬁles in the Supporting Information.
The coeﬃcient of variance (CV) for the LRP-normalized peak
area over triplicate MRM runs was determined for each peptide.
Given the possible eﬀects of formaldehyde ﬁxation chemistry
on lysine C-terminal tryptic peptides, the precision of MRM
measurement was analyzed separately for lysine and arginine C-
terminal peptides. The median CVs for the 52 lysine C-terminal
peptides were not signiﬁcantly diﬀerent between analyses of
ﬁxed (median CV = 0.195) or frozen tissue (median CV =
0.190) using the Mann−Whitney U test (Figure 2). Median
CVs for analyses of the 58 arginine C-terminal peptides also
indicated no signiﬁcant diﬀerence between ﬁxed (median CV =
0.183) or frozen tissue (median CV = 0.180, Figure 2). This
result suggests that there is no discernible eﬀect of form-
aldehyde ﬁxation chemistry that aﬀects the reproducibility of
peptide MRM measurement. In addition, there was no
signiﬁcant diﬀerence in median CV between lysine C-terminal
peptides (median CV = 0.195) and arginine C-terminal
peptides (median CV = 0.183) from FFPE tissue, suggesting
that MRM measurements of FFPE tryptic peptides display
similar technical variation, regardless of the C-terminal amino
acid.
The inﬂuence of ﬁxation status on individual peptides was
further assessed by considering the median CV obtained for
analyses of each peptide across the 5 serial slices (Supporting
Information Table S4). A commonly used method to establish
the limit of quantitation (LOQ) for an analyte is to determine
the average signal at the retention time of interest in a blank
sample plus 8 standard deviations of the average blank signal.
17
For MRM analyses, signals from a blank run at a given peptide
m/z value and retention time can result in very small values,
which can yield theoretical LOQs far below the practical
limitations of the analytical system. A more conservative LOQ
estimate can be obtained empirically by determining the
concentration at which the CV of replicate measurements
exceeds 25%.
17 We thus took this latter approach in our studies.
Of the 114 peptides analyzed, 10 were deemed to be
undetectable due to lack of a consistent signal among replicates
and samples. Of the remaining 104 peptides, 37 yielded median
CVs greater than 25% in the FFPE derived samples. These
peptides were thus designated as being below the LOQ in these
samples. In analyses of frozen tissue digests, 27 peptides
exceeded the 25% median CV threshold (Supporting
Information Table S3). A greater number of peptides below
the LOQ in FFPE tissues may reﬂect reduced signal intensity,
most likely due to reduced tryptic peptide yield in digests of
FFPE samples.
In total, 46 peptides yielded median CVs in excess of 25% in
either FFPE or frozen tissue; 18 of these had median CVs
greater than 25% in both tissue types. Overall, 51% of the
peptides targeted (58/114) yielded signals estimated to be
above the LOQ. This success rate for analyses in FFPE tissues
is comparable to other empirical assessments of proteotypic
peptide suitability in semiquantitative MRM assay development
for biomarker veriﬁcation.
17 As is evident in Supporting
Information Table S3, methods 2 and 3 produced increasing
numbers of peptides exceeding the 25% median CV threshold
and this eﬀect was somewhat greater for FFPE tissue. Peptides
exceeding the threshold were as follows: Method 2, 16 peptides
in FFPE, 9 in frozen; Method 3, 21 in FFPE, 18 in frozen.
Peptides targeted by these two methods were from proteins
represented with fewer spectral counts in the shotgun analysis
(Supporting Information Table S2), indicating lower abun-
dance in the RCC tissues.
The most likely explanation for the eﬀect on median CV in
the FFPE samples is the presence of protein cross-links, which
result in a lower yield of proteotypic tryptic peptides detectable
by MRM analysis, thus decreasing concentrations of the
peptides below the limit of quantitation. The inﬂuence of
ﬁxation appears not to be speciﬁc to a particular class of
protein, or subcellular compartment, but rather is distributed
uniformly among proteins we analyzed. In MRM analyses,
eﬀects on peptide yield will have the greatest impact on
quantiﬁcation of peptides that are already near the limit of
quantitation in unﬁxed, frozen samples. This interpretation is
consistent with our observation here (Figure 1 and Supporting
Information Table 1) and previously
5 that the proteins
represented in shotgun data sets with fewer spectral counts
yield fewer peptide and protein group identiﬁcations in FFPE
tissue than in frozen specimens in shotgun proteomic analysis
of IEF-fractionated samples.
We also considered the eﬀect of ﬁxation on the magnitude of
the peak areas observed during MRM analysis, a more direct
measurement of relative peptide abundance. Of the 114
peptides monitored, 70% showed a signiﬁcant diﬀerence in
average normalized peak area between ﬁxed and frozen samples
(two tailed t test, p < 0.05, Supporting Information Figure 1).
Figure 3 plots the log2 ratio of LRP-normalized peak areas for
peptides from FFPE to frozen tissues. These data demonstrate
that peptides from FFPE tissue generally yield lower
normalized average peak areas than peptides from frozen
tissue, given the predominance of log2 (FFPE:frozen) peptide
intensity values below zero in Figure 3. This result further
illustrates the signiﬁcant impact of ﬁxation on the quantitation
of proteins in tissue.
MRM Quantiﬁcation of the HER2 Receptor Protein
A potentially useful application of MRM quantitative analyses
in FFPE tissue is the measurement of speciﬁc biomarker
Figure 2. CVs for MRM measurements of 52 lysine C-terminal
peptides and 58 arginine C-terminal peptides in 5 serial sections of
frozen and FFPE RCC samples. MRM quantitation was done by the
LRP method. Comparison of median CVs for peptide measurements
from FFPE and frozen tissues indicated no signiﬁcant eﬀect of ﬁxation
on the precision of peptide measurement (Mann−Whitney U test).
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immunohistochemistry (IHC), which can be limited by assay
variability, antibody sensitivity, and speciﬁcity. In addition, IHC
methods are not quantitative and assessment of IHC is
subjective. MRM analyses provide quantitative measurements
with the potential for improved speciﬁcity, thus overcoming key
performance limitations of IHC. To explore the possible clinical
application of MRM in FFPE tissue, we developed an assay to
quantify the HER2 receptor in breast cancer. HER2 over-
expression is a clinically important diagnostic factor in the
management of breast tumors. Ampliﬁcation of HER2 is
observed in 20% of breast cancer cases and patients harboring
HER2-overexpressing tumors are candidates for HER2-targeted
therapies.
To monitor multiple peptides unique to HER2, the peptide
exclusion criteria were relaxed allowing for the inclusion of
peptides containing cysteine, methionine, and histidines.
Peptides were still required to be fully tryptic, between 7 and
25 amino acids in length, unique to HER2 and to be
represented in a reference spectral library. Twenty-ﬁve peptides
met these criteria and were targeted by MRM in a tryptic digest
of the HER2 overexpressing BT474 human breast cancer cell
line. Five transitions were monitored per peptide, as selected
from the most intense y-ions observed in a reference spectral
library. On the basis of this initial screen, 4 peptides were
selected that gave the greatest signal intensity and a CV of less
than 25% when analyzing 1 μg of tryptic digest.
To enable quantitation by stable isotope dilution, labeled
peptides corresponding to these 4 sequences were obtained and
the limit of quantitation was determined in the absence of
biological matrix. Limit of quantitation was deﬁned as the
concentration of peptide where the CV for triplicate measure-
ments exceeded 25%. The peptides DPPFCVAR and
ELVSEFSR provided the greatest sensitivity, yielding limits of
Figure 3. Log2 ratios for average normalized peak areas from FFPE
versus frozen tissues. MRM quantitation was done by the LRP
method. Peptides are ordered on the x-axis in order of decreasing log2
ratios (y-axis values). Equivalent intensities yield a value of zero. Log2
ratios less than zero indicate higher peak areas from peptides derived
from frozen tissue.
Figure 4. MRM chromatograms for the HER2 intracellular domain peptide ELVSEFSR from analyses of FFPE xenograft specimens derived from the
HER2-overexpressing cell line BT474 (left) and the non-HER2-expressing cell line Sum159 (right). MRM quantitation was by stable isotope
dilution. Monitored MRM transitions are depicted for the unlabeled, endogenous peptide, and the isotope-labeled internal standards (insets). The
intensity scales (y-axis) are identical in the two sets of plots.
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fmol on-column, respectively (Supporting Information Figure
2). These limits correspond to a lower limit of detection of 12
000 HER2 receptors per cell, assuming 200 pg protein per cell
and 1 μg tryptic digest on-column (i.e., 5000 cell equivalents
injected for MRM analysis). Detection limits for peptides
GQECVEECR and NPQLCYQDTILWK exceeded 1 fmol on-
column and were not considered for quantitation.
We then analyzed FFPE and frozen xenograft tissue samples
from human BT474 and Sum159 (HER2-negative) breast
cancer cell lines. Whereas signals from HER2 peptides were
readily discernible in BT474 xenografts, HER2 peptide signals
were absent in Sum159 xenografts, consistent with their low
level of HER2 expression (Figure 4). Estimates of HER2
receptor numbers from quantiﬁcation of the DPPFCVAR
peptide were 60% higher than from quantiﬁcation of the
ELVSEFSR peptide. The DPPFCVAR peptide is derived from
the ectodomain of the HER2 receptor, whereas ELVSEFSR is
in the intracellular activation domain of the receptor. This
result could be the result of proteolytic shedding of the receptor
ectodomain. Indeed, BT474 xenografts have been reported to
shed the HER2 extracellular domain into the circulation.
18
To explore the application of MRM for analyses of HER2 in
FFPE human breast tumor tissues, we analyzed 5 HER2-
overexpressing breast cancer tissues and 5 HER2-negative
breast cancers, which had been classiﬁed based on previous
IHC analysis in the Vanderbilt clinical immunohistochemistry
laboratory. MRM analyses of these specimens (Figure 5B)
demonstrate a clear diﬀerence in signal intensity for HER2
peptides between the HER2+ and HER2 negative tumors and
indicate a wide range of biological variability in receptor
expression levels. Quantiﬁcation of receptor levels was
performed by stable isotope dilution. Assuming a yield of 200
pg protein from an average cell, we estimated HER2 receptor
levels ranging from 110 000 to 468 000 receptors per cell in the
HER2 positive cancers and fewer than 14000 receptors per cell
in the HER2 negative cancers. Because of the higher limit of
quantiﬁcation for the DPPFCVAR peptide, it was not possible
to use this peptide to quantify receptor levels in all specimens.
In tissues most highly overexpressing HER2, quantiﬁcation of
receptor levels based on DPPFCVAR yielded the same result as
ELVSEFSR quantiﬁcation, suggesting no evidence of receptor
ectodomain shedding in the tissues analyzed.
■ DISCUSSION
The goal of this work was to assess the performance
characteristics of protein quantitation by MRM in FFPE tissue
and to apply MRM to analyze a clinically relevant biomarker in
human FFPE tissue specimens. Our studies addressed the
hypothesis that protein cross-linking in FFPE tissues would add
to variability in MRM measurements, particularly for lysine C-
terminal peptides. Although peptide yields, particularly for
lysine C-terminal tryptic peptides, are lower in FFPE tissues
than in frozen tissues, measurement variation is not signiﬁcantly
diﬀerent between these specimen types. Median CVs for
analyses of tryptic peptides in FFPE and frozen tissues were all
below 20% and were not signiﬁcantly diﬀerent between
specimen type or between lysine- and arginine C-terminal
peptides. The data not only demonstrate that MRM analyses
can be performed with equal precision on FFPE and frozen
tissues, but also indicate that lysine C-terminal peptides need
not be excluded as MRM candidates when working with FFPE
tissue. Our analyses of HER2 protein in FFPE breast tumor
xenografts and in human FFPE breast tissue specimens
illustrated the feasibility of applying MRM to quantify clinically
important tissue biomarkers.
The major question regarding the use of proteomic methods
to analyze FFPE tissue is the impact of protein cross-linking
that occurs during formalin ﬁxation. The terms “antigen
retrieval” and “crosslink reversal” have been applied to describe
the various protocols to prepare FFPE tissue for IHC
analysis.
19−23 Although these approaches facilitate IHC, there
is no molecular or chemical evidence to demonstrate that
formaldehyde-derived cross-links have been reversed. Indeed,
given the chemical stability of many formaldehyde-derived
covalent cross-links in proteins,
24,25 it is unlikely that any
method or reagent could quantitatively reverse cross-links while
sparing peptide bonds and other functional groups.
Our results suggest the chemical modiﬁcations induced by
formalin ﬁxation decrease the sensitivity of MRM measure-
ments. Thus, somewhat fewer targets are accessible to MRM
when FFPE tissue is analyzed. The fractional loss of peptide
signal is negligible for high-abundance proteins, but proteins
near the limit of quantitation in frozen tissue are less likely to
be accurately quantiﬁed by MRM in FFPE tissue. This
limitation may be overcome to some extent through increased
Figure 5. (A) Quantiﬁcation of HER2 receptor protein in frozen (red
bars) and FFPE (blue bars) BT474 xenograft tissues. HER2 protein
was quantiﬁed based on MRM of peptides representing the
extracellular (DPPFCVAR) and intracellular (ELVSEFSR) domains
of the receptor. MRM quantitation was by stable isotope dilution.
Plotted values are mean ± SD for 3 process replicates of one frozen
and one FFPE tumor. (B) Quantiﬁcation of HER2 receptor protein in
5 human HER2-positive and 5 HER2 negative human FFPE breast
tumor tissues. MRM quantitation was by stable isotope dilution
analysis of peptides representing the extracellular (DPPFCVAR) and
intracellular (ELVSEFSR) domains of HER2. Plotted values are mean
± SD for 3 process replicates of each specimen.
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chromatography columns, permitting injection of larger
amounts of tryptic digest. However, our data indicate that the
overall impact of formalin ﬁxation on peptide yield and signals
was signiﬁcant, yet modest and does not preclude application of
MRM to analyze proteins in FFPE tissues. We should also
point out that, despite the validity of this general conclusion,
certain peptides may be unusually sensitive to formalin ﬁxation
and display high measurement variation in FFPE samples.
Thus, MRM assay development should consider multiple
peptides during assay development and optimization.
We were unable to assess the accuracy of quantitation in
FFPE tissues because the concentrations of the proteins
analyzed were not known. Spike-in experiments with known
amounts of target proteins to assess quantitative accuracy are
not possible with FFPE tissues, as the spiked proteins would
not control for the formalin ﬁxation steps, which probably have
the greatest eﬀect on protein yield. Assessment of accuracy in
MRM analyses of any sample type is complicated by
uncontrolled variability in protein digestion and recovery.
26
However, the goal of MRM analyses usually is comparison of
protein levels, rather than assessment of absolute amounts and
the underlying assumption is that deviations from accuracy are
evenly distributed across all measurements. Precise and
reproducible measurement of relative diﬀerences between
sample classes can enable biomarker veriﬁcation and validation
studies.
To evaluate MRM analyses of FFPE tissues to quantify a
clinically relevant protein biomarker, we analyzed HER2
receptor expression levels in HER2 positive and HER2 negative
breast tumors. HER2 is an important diagnostic and predictive
factor, as patients with HER2-positive tumors are candidates for
anti-HER2 therapies. HER2-positive tumors are deﬁned by
intense membrane staining in the majority of tumor cells (3+
by IHC) using antibodies directed against the HER2 C-
terminus or by expression of ≥2.2 copies of the HER2 gene, as
determined by ﬂuorescent in situ hybridization (FISH).
27 IHC
staining or HER2 copy number determination in FFPE tissue
sections is semiquantitative in nature and results are dependent
on antibody performance and operator experience. Further, the
rate of discordance between IHC and FISH can approach 20%,
which is signiﬁcantly below the maximum rate of 5%
recommended by the American Society of Clinical Oncolo-
gists.
27
An MRM-based approach to analysis of tissue biomarker
proteins oﬀers potential advantages over IHC. Most signiﬁ-
cantly, MRM would allow a systematic approach to
conﬁguration of targeted assays for tissue proteins, even when
antibody reagents validated for IHC are unavailable. This would
remove a major barrier to analysis of protein biomarkers in
FFPE specimens. MRM analyses also provide additional
molecular detail that may not be accessible through IHC. For
example, analyses of HER2 protein with MRM quantitation of
both extracellular and intracellular sequences can extend the
speciﬁcity of molecular characterization of HER2-positive
breast cancers. A potential mechanism of resistance to the
HER2-targeted drug trastuzumab is shedding of the receptor
ectodomain, as HER2 is subject to proteolytic processing at the
plasma membrane by an ADAM or MMP.
28 HER2 measure-
ment based on MRM analysis of intracellular and extracellular
peptide sequences provides a more informative assessment of
the status of the HER2 target than does IHC and FISH. MRM
could further enable analysis of modiﬁed or variant protein
forms, which may be diﬃcult to detect selectively with antibody
reagents.
Our analyses of HER2 in FFPE tissue specimens illustrate
the potential utility of MRM for analysis of a clinically relevant
tissue protein biomarker. The data demonstrate that MRM
analyses are concordant with HER2 status as measured by IHC.
An assessment of the performance of MRM for HER2 or other
tissue biomarkers is beyond the scope of this preliminary study.
Nevertheless, our results demonstrate that MRM analyses in
FFPE and frozen tissues display similar performance character-
istics and that measurement precision in the two tissue types is
essentially identical. Although target peptide yields are lower in
FFPE tissues, this has a modest eﬀect on assay sensitivity. Our
studies were limited to measurements of unmodiﬁed peptides
and may not be applicable to post-translationally modiﬁed (e.g.,
phosphorylated, N-acetylated) sequences, where the stability of
labile modiﬁcations during tissue harvest and ﬁxation may aﬀect
the results. Our ﬁndings indicate that eﬀects of formalin ﬁxation
on tissue proteins does not present major potential barrier to
the development of MRM-based tissue assays for protein
expression for research purposes. The data also suggest that
further development of MRM instrumentation and approaches
may provide powerful new diagnostic tools for the surgical
pathology laboratory.
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